FDA Approves USTEKINUMAB — Janssen Biotech, Inc.

# FDA Approves Janssen Biotech's Ustekinumab Intravenous Formulation Janssen Biotech, Inc. received FDA approval for an intravenous formulation of ustekinumab, expanding the immunosuppressant's market reach beyond subcutaneous administration and positioning the company to capture additional market share in the treatment of inflammatory diseases. The new delivery method could drive increased adoption among patients and healthcare providers, potentially boosting revenues for Janssen's immunology portfolio.